Company intelligence / Profile preview
Gene Signal International SA
- Ownership
- Private
- Development stage
- Other
Overview
Gene Signal developed a pipeline focused on modulating angiogenesis using antisense oligonucleotides, proteins, and monoclonal antibodies. Its lead product, aganirsen (GS‑101), an antisense oligonucleotide eye drop for neovascular-associated corneal graft rejection (NV-CGR), completed or nearly completed Phase III trials by 2013. Additional programs were in Phase II or discovery for other ophthalmic and vascular indications. The company has demonstrated preclinical efficacy in models of retinal neovascular disease and ischemic retinopathy.
- Therapeutic areas
- OphthalmologyOncologyCardiovascularDermatology
- Modalities
- Antisense oligonucleotidesProteinsMonoclonal antibodies
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Gene Signal International SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gene Signal International SA.